Given that the inhibition of mTORC2 has the synergistic anti-MM effects with a proteasome inhibitor and IMiD [51,52], the dual blockade of RSK2 and AKT may be expected to enhance the effects of proteasome inhibitors and IMiDs on myeloma cells. This evidence concerns the gene AKT1 and Miyoshi myopathy.